Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Leukemia Research|November 28, 2006
Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with LenalidomideYing S Zou, Stephanie R Fink, Kimberly J Stockero, et al.
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
Journal of Hematology & Oncology|November 4, 2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)Michael Wang, Stephen J Schuster, Tycel Phillips, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 14, 2013
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatchJames L Slack, Amylou C Dueck, Veena D Fauble, et al.
Blood|June 7, 2014
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaShaji K Kumar, William I Bensinger, Todd M Zimmerman, et al.
British Journal of Haematology|February 17, 2015
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaJoseph R Mikhael, Craig B Reeder, Edward N Libby, et al.
Investigational New Drugs|December 20, 2013
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemiaKevin R Kelly, Thomas C Shea, André Goy, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
Leukemia & Lymphoma|June 24, 2008
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Susan M Geyer, Paul J Kurtin, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2018
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective StudyTania Jain, Heidi E Kosiorek, Shu T Kung, et al.
Pageof 6